Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NEUROLOGICAL BIOMARKERS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL NEUROLOGICAL BIOMARKERS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
5.3 STRATEGIC INITIATIVES
5.4 PIPELINE ANALYSIS
5.5 PATENT ANALYSIS
5.6 RECENT ADVANCES IN BIOMARKERS FOR DEMENTIA WITH LEWY BODIES
6 INDUSTRY INSIGHTS
6.1 KEY PRICING STRATEGIES
6.2 INTERVIEWS WITH PHYSICIANS
6.3 INTERVIEWS WITH MANUFACTURERS
6.4 INTERVIEWS WITH INDUSTRY STAKEHOLDERS
6.5 OTHER KOL SNAPSHOTS
7 EPIDEMOLOGY
8 REGULATORY FRAMWORK
9 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 GENOMICS BIOMARKER
9.3 PROTEOMICS BIOMARKER
9.4 IMAGING BIOMARKER
9.5 METABOLOMICS BIOMARKER
9.6 OTHERS
10 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY INDICATION
10.1 OVERVIEW
10.2 SPINAL MUSCULAR ATROPHY
10.3 PARKINSON'S DISEASE
10.4 SCHIZOPHRENIA
10.5 HUNTINGTON'S DISEASE
10.6 ALZHEIMER'S DISEASE
10.7 DEMENTIA
10.8 DEPRESSION
10.9 MULTIPLE SCLEROSIS
11 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY IMAGING TECHNIQUES
11.1 OVERVIEW
11.2 TRANSCRANIAL MAGNETIC STIMULATION
11.3 DIFFUSION TENSOR IMAGING
11.4 CONVENTIONAL STRUCTURAL MRI
11.5 FUNCTIONAL MAGNETIC RESONANCE IMAGING
11.6 POSITRON EMISSION TOMOGRAPHY
12 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY AGE GROUP
12.1 PEDIATRIC
12.2 ADULT
13 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC LABORATORIES
13.4 ACADEMIC AND RESEARCH ORGANIZATIONS
13.5 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
14 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY GEOGRAPHY
GLOBAL NEUROLOGICAL BIOMARKERS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.1.1. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY PRODUCT TYPE
14.1.1.2. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY INDICATION
14.1.1.3. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY IMAGING TECHNIQUES
14.1.1.4. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY AGE GROUP
14.1.1.5. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY END USER
14.1.2 CANADA
14.1.3 MEXICO
14.2 EUROPE
14.2.1 GERMANY
14.2.2 U.K.
14.2.3 ITALY
14.2.4 FRANCE
14.2.5 SPAIN
14.2.6 RUSSIA
14.2.7 SWITZERLAND
14.2.8 TURKEY
14.2.9 BELGIUM
14.2.10 NETHERLANDS
14.2.11 DENMARK
14.2.12 SWEDEN
14.2.13 POLAND
14.2.14 NORWAY
14.2.15 FINLAND
14.2.16 REST OF EUROPE
14.3 ASIA-PACIFIC
14.3.1 JAPAN
14.3.2 CHINA
14.3.3 SOUTH KOREA
14.3.4 INDIA
14.3.5 SINGAPORE
14.3.6 THAILAND
14.3.7 INDONESIA
14.3.8 MALAYSIA
14.3.9 PHILIPPINES
14.3.10 AUSTRALIA
14.3.11 NEW ZEALAND
14.3.12 REST OF ASIA-PACIFIC
14.4 SOUTH AMERICA
14.4.1 BRAZIL
14.4.2 ARGENTINA
14.4.3 VENEZUELA
14.4.4 PERU
14.4.5 CHILE
14.4.6 REST OF SOUTH AMERICA
14.5 MIDDLE EAST AND AFRICA
14.5.1 SOUTH AFRICA
14.5.2 EGYPT
14.5.3 BAHRAIN
14.5.4 UNITED ARAB EMIRATES
14.5.5 KUWAIT
14.5.6 OMAN
14.5.7 QATAR
14.5.8 SAUDI ARABIA
14.5.9 REST OF MEA
14.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, SWOT AND DBMR ANALYSIS
16 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS
16.2 MERGERS & ACQUISITIONS
16.3 NEW PRODUCT DEVELOPMENT & APPROVALS
16.4 EXPANSIONS
16.5 REGULATORY CHANGES
16.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
17 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY OVERVIEW
17.1.2 GEOGRAPHIC PRESENCE
17.1.3 PRODUCT PORTFOLIO
17.1.4 REVENUE ANALYSIS
17.1.5 RECENT DEVELOPMENTS
17.2 QIAGEN
17.2.1 COMPANY OVERVIEW
17.2.2 GEOGRAPHIC PRESENCE
17.2.3 PRODUCT PORTFOLIO
17.2.4 REVENUE ANALYSIS
17.2.5 RECENT DEVELOPMENTS
17.3 Q2 SOLUTIONS
17.3.1 COMPANY OVERVIEW
17.3.2 GEOGRAPHIC PRESENCE
17.3.3 PRODUCT PORTFOLIO
17.3.4 REVENUE ANALYSIS
17.3.5 RECENT DEVELOPMENTS
17.4 F. HOFFMANN-LA ROCHE LTD
17.4.1 COMPANY OVERVIEW
17.4.2 GEOGRAPHIC PRESENCE
17.4.3 PRODUCT PORTFOLIO
17.4.4 REVENUE ANALYSIS
17.4.5 RECENT DEVELOPMENTS
17.5 IMAGILYS
17.5.1 COMPANY OVERVIEW
17.5.2 GEOGRAPHIC PRESENCE
17.5.3 PRODUCT PORTFOLIO
17.5.4 REVENUE ANALYSIS
17.5.5 RECENT DEVELOPMENTS
17.6 AMPRION INC.
17.6.1 COMPANY OVERVIEW
17.6.2 GEOGRAPHIC PRESENCE
17.6.3 PRODUCT PORTFOLIO
17.6.4 REVENUE ANALYSIS
17.6.5 RECENT DEVELOPMENTS
17.7 ADX NEUROSCIENCES NV
17.7.1 COMPANY OVERVIEW
17.7.2 GEOGRAPHIC PRESENCE
17.7.3 PRODUCT PORTFOLIO
17.7.4 REVENUE ANALYSIS
17.7.5 RECENT DEVELOPMENTS
17.8 QUANTERIX
17.8.1 COMPANY OVERVIEW
17.8.2 GEOGRAPHIC PRESENCE
17.8.3 PRODUCT PORTFOLIO
17.8.4 REVENUE ANALYSIS
17.8.5 RECENT DEVELOPMENTS
17.9 ELI LILLY AND COMPANY
17.9.1 COMPANY OVERVIEW
17.9.2 GEOGRAPHIC PRESENCE
17.9.3 PRODUCT PORTFOLIO
17.9.4 REVENUE ANALYSIS
17.9.5 RECENT DEVELOPMENTS
17.1 MERCK KGAA
17.10.1 COMPANY OVERVIEW
17.10.2 GEOGRAPHIC PRESENCE
17.10.3 PRODUCT PORTFOLIO
17.10.4 REVENUE ANALYSIS
17.10.5 RECENT DEVELOPMENTS
17.11 ATHENA DIAGNOSTICS, INC.
17.11.1 COMPANY OVERVIEW
17.11.2 GEOGRAPHIC PRESENCE
17.11.3 PRODUCT PORTFOLIO
17.11.4 REVENUE ANALYSIS
17.11.5 RECENT DEVELOPMENTS
17.12 BIO-RAD LABORATORIES, INC.
17.12.1 COMPANY OVERVIEW
17.12.2 GEOGRAPHIC PRESENCE
17.12.3 PRODUCT PORTFOLIO
17.12.4 REVENUE ANALYSIS
17.12.5 RECENT DEVELOPMENTS
17.13 BIOMÉRIEUX INC.
17.13.1 COMPANY OVERVIEW
17.13.2 GEOGRAPHIC PRESENCE
17.13.3 PRODUCT PORTFOLIO
17.13.4 REVENUE ANALYSIS
17.13.5 RECENT DEVELOPMENTS
17.14 JANSSEN GLOBAL SERVICES, LLC
17.14.1 COMPANY OVERVIEW
17.14.2 GEOGRAPHIC PRESENCE
17.14.3 PRODUCT PORTFOLIO
17.14.4 REVENUE ANALYSIS
17.14.5 RECENT DEVELOPMENTS
17.15 CHARLES RIVER LABORATORIES.
17.15.1 COMPANY OVERVIEW
17.15.2 GEOGRAPHIC PRESENCE
17.15.3 PRODUCT PORTFOLIO
17.15.4 REVENUE ANALYSIS
17.15.5 RECENT DEVELOPMENTS
17.16 ADVANCED BRAIN MONITORING, INC.
17.16.1 COMPANY OVERVIEW
17.16.2 GEOGRAPHIC PRESENCE
17.16.3 PRODUCT PORTFOLIO
17.16.4 REVENUE ANALYSIS
17.16.5 RECENT DEVELOPMENTS
17.17 NEUROSTEER INC.
17.17.1 COMPANY OVERVIEW
17.17.2 GEOGRAPHIC PRESENCE
17.17.3 PRODUCT PORTFOLIO
17.17.4 REVENUE ANALYSIS
17.17.5 RECENT DEVELOPMENTS
17.18 AC IMMUNE SA
17.18.1 COMPANY OVERVIEW
17.18.2 GEOGRAPHIC PRESENCE
17.18.3 PRODUCT PORTFOLIO
17.18.4 REVENUE ANALYSIS
17.18.5 RECENT DEVELOPMENTS
17.19 AXON NEUROSCIENCE
17.19.1 COMPANY OVERVIEW
17.19.2 GEOGRAPHIC PRESENCE
17.19.3 PRODUCT PORTFOLIO
17.19.4 REVENUE ANALYSIS
17.19.5 RECENT DEVELOPMENTS
17.2 EATRIS ERIC
17.20.1 COMPANY OVERVIEW
17.20.2 GEOGRAPHIC PRESENCE
17.20.3 PRODUCT PORTFOLIO
17.20.4 REVENUE ANALYSIS
17.20.5 RECENT DEVELOPMENTS
17.21 CEREBRAL THERAPEUTICS, INC.
17.21.1 COMPANY OVERVIEW
17.21.2 GEOGRAPHIC PRESENCE
17.21.3 PRODUCT PORTFOLIO
17.21.4 REVENUE ANALYSIS
17.21.5 RECENT DEVELOPMENTS
17.22 PERKINELMER INC.
17.22.1 COMPANY OVERVIEW
17.22.2 GEOGRAPHIC PRESENCE
17.22.3 PRODUCT PORTFOLIO
17.22.4 REVENUE ANALYSIS
17.22.5 RECENT DEVELOPMENTS
17.23 ALTOIDA
17.23.1 COMPANY OVERVIEW
17.23.2 GEOGRAPHIC PRESENCE
17.23.3 PRODUCT PORTFOLIO
17.23.4 REVENUE ANALYSIS
17.23.5 RECENT DEVELOPMENTS
17.24 FUJIREBIO
17.24.1 COMPANY OVERVIEW
17.24.2 GEOGRAPHIC PRESENCE
17.24.3 PRODUCT PORTFOLIO
17.24.4 REVENUE ANALYSIS
17.24.5 RECENT DEVELOPMENTS
17.25 HYTEST LTD
17.25.1 COMPANY OVERVIEW
17.25.2 GEOGRAPHIC PRESENCE
17.25.3 PRODUCT PORTFOLIO
17.25.4 REVENUE ANALYSIS
17.25.5 RECENT DEVELOPMENTS
17.26 RAYBIOTECH LIFE, INC.
17.26.1 COMPANY OVERVIEW
17.26.2 GEOGRAPHIC PRESENCE
17.26.3 PRODUCT PORTFOLIO
17.26.4 REVENUE ANALYSIS
17.26.5 RECENT DEVELOPMENTS
17.27 ABCAM PLC.
17.27.1 COMPANY OVERVIEW
17.27.2 GEOGRAPHIC PRESENCE
17.27.3 PRODUCT PORTFOLIO
17.27.4 REVENUE ANALYSIS
17.27.5 RECENT DEVELOPMENTS
17.28 ICON PLC
17.28.1 COMPANY OVERVIEW
17.28.2 GEOGRAPHIC PRESENCE
17.28.3 PRODUCT PORTFOLIO
17.28.4 REVENUE ANALYSIS
17.28.5 RECENT DEVELOPMENTS
17.29 LABORATORY CORPORATION OF AMERICA HOLDINGS.
17.29.1 COMPANY OVERVIEW
17.29.2 GEOGRAPHIC PRESENCE
17.29.3 PRODUCT PORTFOLIO
17.29.4 REVENUE ANALYSIS
17.29.5 RECENT DEVELOPMENTS
17.3 NQ MEDICAL.
17.30.1 COMPANY OVERVIEW
17.30.2 GEOGRAPHIC PRESENCE
17.30.3 PRODUCT PORTFOLIO
17.30.4 REVENUE ANALYSIS
17.30.5 RECENT DEVELOPMENTS
17.31 CREATIVE BIOLABS.
17.31.1 COMPANY OVERVIEW
17.31.2 GEOGRAPHIC PRESENCE
17.31.3 PRODUCT PORTFOLIO
17.31.4 REVENUE ANALYSIS
17.31.5 RECENT DEVELOPMENTS
17.32 OLINK
17.32.1 COMPANY OVERVIEW
17.32.2 GEOGRAPHIC PRESENCE
17.32.3 PRODUCT PORTFOLIO
17.32.4 REVENUE ANALYSIS
17.32.5 RECENT DEVELOPMENTS
17.33 RESONANCE HEALTH LTD
17.33.1 COMPANY OVERVIEW
17.33.2 GEOGRAPHIC PRESENCE
17.33.3 PRODUCT PORTFOLIO
17.33.4 REVENUE ANALYSIS
17.33.5 RECENT DEVELOPMENTS
18 RELATED REPORTS
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
